Jafron Biomedical Co Ltd

Jafron Biomedical Co Ltd has a market capitalization of 15.25 billion CNY and a price-to-earnings ratio of 28.61, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio of 4.39 suggests that the market is valuing its equity at a premium to its book value. The enterprise value to EBITDA ratio of 23.92 indicates that the company is trading at a multiple that is typical for its industry. The company's profitability is reflected in its return on equity of 15.35% and return on assets of 9.85%, both of which are strong indicators of efficient use of equity and assets. The gross profit margin of 78.1% and operating margin of 34.3% suggest that the company is effectively managing its production and operational costs. The net income of 532.82 million CNY demonstrates the company's ability to convert revenue into profit. Jafron Biomedical Co Ltd's capital structure is characterized by a debt-to-equity ratio of 0.36, indicating a relatively conservative use of debt financing. The company's total liabilities of 1.94 billion CNY are significantly lower than its total equity of 3.47 billion CNY, suggesting a strong equity base. The current ratio of 5.81 indicates that the company has a strong short-term liquidity position. The company's revenue of 2.01 billion CNY and operating cash flow of 721.22 million CNY suggest a healthy cash flow generation capability. However, the free cash flow of -161.98 million CNY indicates that the company is currently investing more in capital expenditures than it is generating in free cash. The capital expenditure of -172.59 million CNY suggests that the company is investing in its long-term growth. The risk assessment for Jafron Biomedical Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could pose a liquidity challenge if not managed properly. The company's shares outstanding are the same for both basic and diluted shares, indicating no immediate dilution pressure. Recent analyst estimates suggest a strong buy sentiment with a mean price target of 24.23 CNY and a mean recommendation of 1.00. The strong-buy count of 2.00 and the absence of buy or hold recommendations indicate a positive outlook from analysts. The uniformity of the price targets suggests a consensus among analysts regarding the company's future performance.